To develop a DoD capacity to rapidly develop and produce medical countermeasures (MCMs) to counter known or unknown chemical, biological, radiological, and nuclear (CBRN) threats, including novel and previously unrecognized naturally occurring emerging infectious diseases.
ADMC is managing the building of a centralized facility for advanced research, development, and manufacture of MCMs to support biodefense innovators including biotechnology companies, academia, and R&D labs.
ADMC offers a full range of core services
- Manufacturing and testing
- Regulatory strategies to meet FDA requirements
- Clinical and nonclinical studies
The successful establishment of the ADMC allows DoD to more efficiently develop MCMs to protect and treat our armed forces against CBRN attacks and outbreaks of naturally occurring, emerging, and genetically engineered infectious diseases.
ADMC provides a full spectrum of medical product functions including research, manufacturing, nonclinical and clinical development, and fill-finish operations. These capabilities are available through DoD’s contractor, Nanotherapeutics, Inc., and its various partner organizations.
This dedicated pharmaceutical manufacturing facility will use state-of-the-art techniques to meet DoD’s needs in 2015 and beyond.